<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01011413</url>
  </required_header>
  <id_info>
    <org_study_id>NCHECR-ENCORE1</org_study_id>
    <nct_id>NCT01011413</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Reduced Versus Standard Dose Efavirenz (EFV) Plus Two Nucleotides in Antiretroviral-naïve Adults.</brief_title>
  <acronym>ENCORE1</acronym>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Trial to Compare the Safety and Efficacy of Reduced Dose Versus Standard Dose EFV Plus Two Nucleotides (N(t)RTI) in Antiretroviral-naïve HIV-infected Adults Over 96 Weeks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kirby Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical data suggests that the standard dose of the anti-HIV medication, efavirenz (EFV),
      could be reduced without compromising its effectiveness. Lower drug doses could have fewer
      side effects and would make EFV more affordable. The purpose of this study is to compare the
      safety and effectiveness, over 96 weeks, of standard (600mg) versus reduced dose (400mg) EFV
      in controlling HIV as part of initial combination antiretroviral therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this international, multicenter trial, 630 HIV infected patients who have not received any
      previous treatment for their HIV-infection will be enrolled. Participants will be randomized
      equally (1:1) to receive Truvada (tenofovir and emtricitabine) with either the standard or
      reduced dose of EFV. Neither the study doctor nor the participant will know which treatment
      the participant is receiving. Physical examinations, laboratory analyses and questionnaires
      will be performed at the 11 study visits at screening, baseline (Week 0), Weeks 4, 12, 24,
      36, 48, 60, 72, 84 and 96. The primary aim of this study is to compare between treatment
      groups the proportion of patients with undetectable HIV viral load (HIV RNA &lt; 200 copies/mL)
      after 48 weeks. Information on immune function, drug adherence, resistance to
      antiretrovirals, quality of life, mental state and HIV-related conditions will also be
      collected. Blood samples will be collected for future testing. Interim analyses will be
      performed when the first 125 participants in each treatment group reach week 24 and when all
      participants reach week 24. These interim analyses will provide an early check that the
      reduced dose of EFV suppresses HIV infection as effectively as the standard dose of EFV. A
      follow-up analysis will be performed when all participants reach week 96.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Plasma HIV-1 RNA &lt;200 Copies/mL 48 Weeks After Randomisation</measure>
    <time_frame>48 weeks</time_frame>
    <description>Percentage of participants in each of the treatment arms with centrally quantified plasma HIV-1 RNA viral load &lt;200 copies/mL 48 weeks after randomisation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Plasma HIV-1 RNA &lt;400 Copies/mL and &lt;50 Copies/mL at 48 and 96 Weeks After Randomisation</measure>
    <time_frame>Baseline and 2 years</time_frame>
    <description>Percentage of participants in each of the two treatment arms with plasma HIV-1 RNA &lt;400 copies/mL and &lt;50 copies/mL at 48 and 96 weeks after randomisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in CD4+ T-cell Count</measure>
    <time_frame>Baseline and 2 years</time_frame>
    <description>Mean change from baseline to week 96 in CD4+ T-cell count/mm3 between the two treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Endpoints: Opportunistic Disease or Death, and Serious Non-AIDS-defining Events and Non-AIDS-related Mortality</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Number of participants in each randomised arm diagnosed with a serious non-AIDS defining event, who die from an AIDS-defining event, who die from a non-AIDS-defining event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Metabolic Endpoints</measure>
    <time_frame>Baseline and 2 years</time_frame>
    <description>Change from baseline to week 96 in fasted total cholesterol, high density cholesterol and low density cholesterol, and glucose between randomised treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence: Median Scores of Self-reported Adherence to Randomised Study Medications</measure>
    <time_frame>2 years</time_frame>
    <description>AIDS Clinical Trials Group (ACTG) 7-day adherence questionnaire scores. Maximum value is all pills taken every day; minimum value is no pills taken per day. Higher scores indicate a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasted Insulin Levels</measure>
    <time_frame>Baseline and 2 years</time_frame>
    <description>Change from baseline to week 96 in fasted insulin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Selected Serum Biochemical Parameters</measure>
    <time_frame>Baseline and 2 years</time_frame>
    <description>Change from baseline to week 96 in alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase levels between randomised treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Estimate Creatinine Clearance</measure>
    <time_frame>Baseline and 2 years</time_frame>
    <description>Change from baseline to week 96 in estimate creatinine clearance between randomised treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady-state Efavirenz Concentrations</measure>
    <time_frame>Week 4</time_frame>
    <description>Steady-state efavirenz mid-dosing interval plasma concentrations</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">636</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>600 milligram (mg) Efavirenz</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eligible patients will be centrally randomised to receive tenofovir (TDF) (300mg qd)/emtricitabine (FTC) (200mg qd) + EFV (600mg qd; 3 x 200mg qd)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>400mg Efavirenz</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients will be centrally randomised to receive TDF (300mg qd)/FTC (200mg qd) + EFV (400mg qd; 2 x 200mg + 1 x 200mg placebo qd).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz 600mg</intervention_name>
    <description>3 x EFV 200 milligram (mg) tablets once daily</description>
    <arm_group_label>600 milligram (mg) Efavirenz</arm_group_label>
    <other_name>Matrix EFV 200mg tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz 400mg</intervention_name>
    <description>2 x EFV 200 milligram (mg) tablets plus 1x matched EFV placebo tablet once daily</description>
    <arm_group_label>400mg Efavirenz</arm_group_label>
    <other_name>Matrix EFV 200mg tablets</other_name>
    <other_name>Matrix EFV 200mg matched placebo tablets.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 positive by licensed diagnostic test

          -  aged &gt;16 years of age (or minimum age as determined by local regulations or as legal
             requirements dictate)

          -  50 &lt; cluster of differentiation (CD)4 &lt;500 cells/µL

          -  No prior AIDS-defining illness, using the Center for Diseases Control 1993 Case
             Definition (except pulmonary tuberculosis)

          -  HIV RNA ≥1000 copies/mL

          -  no prior exposure to antiretroviral therapy (ART) (including short course ART for
             preventing MTCT)

          -  calculated creatinine clearance (CLCr) more than or equal to 50 mL/min
             (Cockcroft-Gault formula)

          -  provision of written informed consent.

        Exclusion Criteria:

          -  the following laboratory values:

               -  absolute neutrophil count (ANC) &lt;500 cells/μL

               -  hemoglobin &lt;7.0 g/dL

               -  platelet count &lt;50,000 cells/μL

               -  alanine aminotransferase and/or aspartate aminotransferase &gt;5 x upper limit of
                  normal

          -  pregnant women or nursing mothers

          -  active opportunistic or malignant disease not under adequate control

          -  use of immunomodulators within 30 days prior to screening

          -  use of any prohibited medications

          -  current alcohol or illicit substance use that might adversely affect study
             participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Cooper, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kirby Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>https://kirby.unsw.edu.au</url>
    <description>Kirby Institute (formerly National Centre for HIV Epidemiology and Clinical Research)</description>
  </link>
  <results_reference>
    <citation>ENCORE1 Study Group. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet. 2014 Apr 26;383(9927):1474-1482. doi: 10.1016/S0140-6736(13)62187-X. Epub 2014 Feb 10. Erratum in: Lancet. 2014 Apr 26;383(9927):1464.</citation>
    <PMID>24522178</PMID>
  </results_reference>
  <results_reference>
    <citation>ENCORE1 Study Group, Carey D, Puls R, Amin J, Losso M, Phanupak P, Foulkes S, Mohapi L, Crabtree-Ramirez B, Jessen H, Kumar S, Winston A, Lee MP, Belloso W, Cooper DA, Emery S. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infect Dis. 2015 Jul;15(7):793-802. doi: 10.1016/S1473-3099(15)70060-5. Epub 2015 Apr 12. Erratum in: Lancet Infect Dis. 2015 Jul;15(7):761.</citation>
    <PMID>25877963</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 9, 2009</study_first_submitted>
  <study_first_submitted_qc>November 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2009</study_first_posted>
  <results_first_submitted>February 22, 2018</results_first_submitted>
  <results_first_submitted_qc>February 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 21, 2020</results_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Antiretroviral Therapy (ART)</keyword>
  <keyword>Efavirenz (EFV)</keyword>
  <keyword>Dose reduction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>38 clinical centres (primary and tertiary care facilities) in 13 countries on 5 continents screened a total of 768 patents who had provided informed consent between Aug 4, 2011 and March 19, 2012.</recruitment_details>
      <pre_assignment_details>768 screened:132 did not satisfy eligibility: 2 prior AIDS-defining illness; 3 previous antiretroviral therapy; 15 HIV RNA out of range; 44 cluster of differentiation (CD)4 count out of range; 13 lab values out of range; 2 pregnant; 9 intercurrent illness; 2 illicit substance use; 30 exceeded screen time; 4 clinician exclusion; 9 withdrew consent.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>600mg Efavirenz</title>
          <description>Eligible patients will be centrally randomised to receive tenofovir (TDF) (300mg qd)/emtricitabine (FTC) (200mg qd) + EFV (600mg qd; 3 x 200mg qd)
Efavirenz: 3 x EFV 200mg tablets once daily</description>
        </group>
        <group group_id="P2">
          <title>400mg Efavirenz</title>
          <description>Eligible patients will be centrally randomised to receive TDF (300mg qd)/FTC (200mg qd) + EFV (400mg qd; 2 x 200mg + 1 x 200mg placebo qd).
Efavirenz: 2 x EFV 200mg tablets plus 1x matched EFV placebo tablet once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="312">312 randomised</participants>
                <participants group_id="P2" count="324">324 randomised</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Did Not Start Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>In Modified ITT</title>
              <participants_list>
                <participants group_id="P1" count="309"/>
                <participants group_id="P2" count="321"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Died Before Week 48</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Lost to Follow up Before w48</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Withdrew Consent Before w48</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Attended w48 Visit</title>
              <participants_list>
                <participants group_id="P1" count="295"/>
                <participants group_id="P2" count="311"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Died Between Week 48 and 96</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Withdrew Consent Between Week 48 and 96</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Lost to Follow-up Between Week 48 and 96</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="286"/>
                <participants group_id="P2" count="299"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>600mg Efavirenz</title>
          <description>Eligible patients will be centrally randomised to receive tenofovir (TDF) (300mg qd)/emtricitabine (FTC) (200mg qd) + EFV (600mg qd; 3 x 200mg qd)
Efavirenz: 3 x EFV 200mg tablets once daily</description>
        </group>
        <group group_id="B2">
          <title>400mg Efavirenz</title>
          <description>Eligible patients will be centrally randomised to receive TDF (300mg qd)/FTC (200mg qd) + EFV (400mg qd; 2 x 200mg + 1 x 200mg placebo qd).
Efavirenz: 2 x EFV 200mg tablets plus 1x matched EFV placebo tablet once daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="309"/>
            <count group_id="B2" value="321"/>
            <count group_id="B3" value="630"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.8" spread="10.0"/>
                    <measurement group_id="B2" value="36.1" spread="10.0"/>
                    <measurement group_id="B3" value="36.0" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="203"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="206"/>
                    <measurement group_id="B2" value="221"/>
                    <measurement group_id="B3" value="427"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                    <measurement group_id="B2" value="118"/>
                    <measurement group_id="B3" value="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV transmission risk</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>heterosexual</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="156"/>
                    <measurement group_id="B2" value="156"/>
                    <measurement group_id="B3" value="312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>homo/bisexual</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="134"/>
                    <measurement group_id="B2" value="138"/>
                    <measurement group_id="B3" value="272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>injecting drug user/not known</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CDC HIV infection clinical category</title>
          <description>As assessed by the Centres for Disease Control and Prevention (CDC) 1993 Revised Classification System for HIV Infection for Adolescents and Adults. Published in Morbidity and Mortality Weekly Report December 18, 1992 / 41(RR-17). Clinical category of HIV infection was assigned by the clinician based on the clinical conditions that define each of the three categories. Category A is the best, followed by category B and lastly category C.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>category A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="265"/>
                    <measurement group_id="B2" value="264"/>
                    <measurement group_id="B3" value="529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>category B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>category C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Median plasma HIV RNA</title>
          <units>log10 copies per mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.73" lower_limit="3.83" upper_limit="5.63"/>
                    <measurement group_id="B2" value="4.76" lower_limit="3.92" upper_limit="5.60"/>
                    <measurement group_id="B3" value="4.75" lower_limit="3.87" upper_limit="5.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean nadir cluster of differentiation (CD)4+ cell count</title>
          <units>cells per mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="252" spread="90"/>
                    <measurement group_id="B2" value="248" spread="88"/>
                    <measurement group_id="B3" value="250" spread="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hep B Sag +ve</title>
          <description>number of participants surface antigen positive</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hep C ab +ve</title>
          <description>number of participants antibody positive</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean creatinine clearance (mL/min)</title>
          <units>mL per min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120" spread="32.4"/>
                    <measurement group_id="B2" value="117.4" spread="29.7"/>
                    <measurement group_id="B3" value="118.7" spread="31.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean total chol (mmol/L)</title>
          <units>mmol per Litre</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.15" spread="0.93"/>
                    <measurement group_id="B2" value="4.24" spread="0.95"/>
                    <measurement group_id="B3" value="4.20" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean HDL chol (mmol/L)</title>
          <units>mmol per Litre</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.03" spread="0.31"/>
                    <measurement group_id="B2" value="1.04" spread="0.32"/>
                    <measurement group_id="B3" value="1.03" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean LDL chol (mmol/L)</title>
          <units>mmol per Litre</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.47" spread="0.84"/>
                    <measurement group_id="B2" value="2.54" spread="0.93"/>
                    <measurement group_id="B3" value="2.51" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean triglycerides (mmol/L)</title>
          <units>mmol per Litre</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.24" spread="0.69"/>
                    <measurement group_id="B2" value="1.25" spread="0.72"/>
                    <measurement group_id="B3" value="1.25" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insulin (mU/L)</title>
          <units>mU per Litre</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.28" spread="9.70"/>
                    <measurement group_id="B2" value="8.26" spread="12.9"/>
                    <measurement group_id="B3" value="8.27" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glucose (mmol/L)</title>
          <units>mmol per Litre</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.84" spread="1.78"/>
                    <measurement group_id="B2" value="4.66" spread="0.98"/>
                    <measurement group_id="B3" value="4.75" spread="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current smoker</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean BMI (kg/m^2)</title>
          <units>kg per m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.3" spread="5.2"/>
                    <measurement group_id="B2" value="24.0" spread="4.7"/>
                    <measurement group_id="B3" value="24.2" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Plasma HIV-1 RNA &lt;200 Copies/mL 48 Weeks After Randomisation</title>
        <description>Percentage of participants in each of the treatment arms with centrally quantified plasma HIV-1 RNA viral load &lt;200 copies/mL 48 weeks after randomisation.</description>
        <time_frame>48 weeks</time_frame>
        <population>modified intention to treat including all randomised patients who took at least one dose of study medication AND attended at least one follow-up visit.</population>
        <group_list>
          <group group_id="O1">
            <title>600mg Efavirenz</title>
            <description>Efavirenz: 3 x EFV 200mg tablets once daily plus tenofovir/emtricitabine 300 mg/200 mg</description>
          </group>
          <group group_id="O2">
            <title>400mg Efavirenz</title>
            <description>Efavirenz: 2 x EFV 200mg tablets plus 1x matched EFV placebo tablet once daily plus tenofovir/emtricitabine 300 mg/200 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Plasma HIV-1 RNA &lt;200 Copies/mL 48 Weeks After Randomisation</title>
          <description>Percentage of participants in each of the treatment arms with centrally quantified plasma HIV-1 RNA viral load &lt;200 copies/mL 48 weeks after randomisation.</description>
          <population>modified intention to treat including all randomised patients who took at least one dose of study medication AND attended at least one follow-up visit.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="321"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.2" lower_limit="89.2" upper_limit="95.2"/>
                    <measurement group_id="O2" value="94.1" lower_limit="91.5" upper_limit="96.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sample size calculation assumes 85% of participants randomised to 600mg EFV arm will have plasma HIV RNA &lt;200 copies/ml at 48 weeks. Assuming no difference between randomised treatments in proportion with plasma HIV RNA &lt;200 copies/mL, to have 90% power to demonstrate non-inferiority in the intention to treat (ITT) analysis using a 10% non-inferiority margin will require 286 participants per arm, making a total of 572 participants. Power for modified ITT analysis was 93%.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Only the primary endpoint is assessed in terms of non-inferiority. All other comparisons are tests for superiority and are considered statistically significant at a two-sided alpha=0.05.
Non-inferiority of EFV 400 mg was defined as the lower 95% confidence interval (CI) of the difference between groups in the proportion of viral load below 200 copies/mL at week 48 lying above -10%.</non_inferiority_desc>
            <p_value>0.05</p_value>
            <p_value_desc>No adjustments were made for multiple comparisons</p_value_desc>
            <method>Pearson's chi-squared</method>
            <method_desc>Pearson's chi-squared or Fisher's exact test derived p value was used</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>To ensure the per protocol (PP) analysis has 90% power to demonstrate non-inferiority, the sample size was inflated for patients who switch treatment for toxicity. This is estimated to be no more than 10% randomised patients. To ensure 90% power to demonstrate non-inferiority in the ITT and PP analyses, a total of 630 (315 per arm) patients will be randomised giving 93% power for the ITT analysis. Null hypothesis: no statistically significant difference between the 600mg and 400mg EFV regimens.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority will be defined as the lower 95% confidence limit of the difference in percentages of patients with undetectable viral load lying above -10% (i.e. a non-inferiority margin of 10%).</non_inferiority_desc>
            <p_value>0.05</p_value>
            <p_value_desc>No adjustment for multiple comparisons</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Plasma HIV-1 RNA &lt;400 Copies/mL and &lt;50 Copies/mL at 48 and 96 Weeks After Randomisation</title>
        <description>Percentage of participants in each of the two treatment arms with plasma HIV-1 RNA &lt;400 copies/mL and &lt;50 copies/mL at 48 and 96 weeks after randomisation</description>
        <time_frame>Baseline and 2 years</time_frame>
        <population>Modified ITT including all randomised participants who took at least one dose of study medication and attended at least one follow-up visit</population>
        <group_list>
          <group group_id="O1">
            <title>600 mg Efavirenz</title>
            <description>EFV 600 mg plus tenofovir 300 mg and emtricitabine 200 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Efavirenz 400 mg</title>
            <description>EFV 400 mg plus tenofovir 300 mg and emtricitabine 200 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Plasma HIV-1 RNA &lt;400 Copies/mL and &lt;50 Copies/mL at 48 and 96 Weeks After Randomisation</title>
          <description>Percentage of participants in each of the two treatment arms with plasma HIV-1 RNA &lt;400 copies/mL and &lt;50 copies/mL at 48 and 96 weeks after randomisation</description>
          <population>Modified ITT including all randomised participants who took at least one dose of study medication and attended at least one follow-up visit</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="321"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HIV-1 RNA &lt;50cp/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="268"/>
                    <measurement group_id="O2" value="277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HIV-1 RNA &lt;400cp/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="280"/>
                    <measurement group_id="O2" value="291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.05</p_value>
            <p_value_desc>P-value not adjusted for multiple comparisons</p_value_desc>
            <method>Chi-squared</method>
            <param_type>difference between proportions</param_type>
            <param_value>0.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in CD4+ T-cell Count</title>
        <description>Mean change from baseline to week 96 in CD4+ T-cell count/mm3 between the two treatment arms</description>
        <time_frame>Baseline and 2 years</time_frame>
        <population>modified ITT (all participants who received at least one dose of study treatment and attended at least one follow up visit, irrespective of treatment received)</population>
        <group_list>
          <group group_id="O1">
            <title>600mg Efavirenz</title>
            <description>Efavirenz 600mg: 3 x EFV 200 mg tablets once daily plus tenofovir/emtricitabine 300 mg /200 mg</description>
          </group>
          <group group_id="O2">
            <title>400mg Efavirenz</title>
            <description>Efavirenz 400 MG: 2 x EFV 200 milligram (mg) tablets plus 1x matched EFV placebo tablet once daily plus tenofovir/emtricitabine 300 mg/200 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in CD4+ T-cell Count</title>
          <description>Mean change from baseline to week 96 in CD4+ T-cell count/mm3 between the two treatment arms</description>
          <population>modified ITT (all participants who received at least one dose of study treatment and attended at least one follow up visit, irrespective of treatment received)</population>
          <units>cells per mm3</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="321"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209" lower_limit="194" upper_limit="226"/>
                    <measurement group_id="O2" value="235" lower_limit="218" upper_limit="252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Endpoints: Opportunistic Disease or Death, and Serious Non-AIDS-defining Events and Non-AIDS-related Mortality</title>
        <description>Number of participants in each randomised arm diagnosed with a serious non-AIDS defining event, who die from an AIDS-defining event, who die from a non-AIDS-defining event</description>
        <time_frame>up to 2 years</time_frame>
        <population>modified ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>600mg Efavirenz</title>
            <description>Efavirenz 600mg: 3 x EFV 200 mg tablets once daily plus tenofovir/emtricitabine 300 mg/200 mg</description>
          </group>
          <group group_id="O2">
            <title>400mg Efavirenz</title>
            <description>Efavirenz 400 MG: 2 x EFV 200mg tablets plus 1x matched EFV placebo tablet once daily plus tenofovir/emtricitabine 300 mg/200 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Endpoints: Opportunistic Disease or Death, and Serious Non-AIDS-defining Events and Non-AIDS-related Mortality</title>
          <description>Number of participants in each randomised arm diagnosed with a serious non-AIDS defining event, who die from an AIDS-defining event, who die from a non-AIDS-defining event</description>
          <population>modified ITT population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="321"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>AIDS events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>AIDS event deaths</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>non-AIDS deaths</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>serious non-AIDS events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No disease/death</title>
                  <measurement_list>
                    <measurement group_id="O1" value="292"/>
                    <measurement group_id="O2" value="301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Metabolic Endpoints</title>
        <description>Change from baseline to week 96 in fasted total cholesterol, high density cholesterol and low density cholesterol, and glucose between randomised treatment arms</description>
        <time_frame>Baseline and 2 years</time_frame>
        <population>Available data analysis</population>
        <group_list>
          <group group_id="O1">
            <title>600mg Efavirenz</title>
            <description>Efavirenz 600mg: 3 x EFV 200mg once daily plus tenofovir/emtricitabine 300 mg/200 mg tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>400mg Efavirenz</title>
            <description>Efavirenz 400 MG: 2 x EFV 200mg tablets plus 1x matched EFV placebo tablet once daily plus tenofovir/emtricitabine 300 mg/200 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Metabolic Endpoints</title>
          <description>Change from baseline to week 96 in fasted total cholesterol, high density cholesterol and low density cholesterol, and glucose between randomised treatment arms</description>
          <population>Available data analysis</population>
          <units>mmol per Litre</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="321"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total cholesterol mmol/L</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="279"/>
                    <count group_id="O2" value="292"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" lower_limit="0.53" upper_limit="0.71"/>
                    <measurement group_id="O2" value="0.54" lower_limit="0.44" upper_limit="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL mmol/L</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="273"/>
                    <count group_id="O2" value="286"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" lower_limit="0.31" upper_limit="0.40"/>
                    <measurement group_id="O2" value="0.30" lower_limit="0.26" upper_limit="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL mmol/L</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="271"/>
                    <count group_id="O2" value="283"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" lower_limit="0.13" upper_limit="0.29"/>
                    <measurement group_id="O2" value="0.16" lower_limit="0.09" upper_limit="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood glucose mmol/L</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="281"/>
                    <count group_id="O2" value="293"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" lower_limit="0.07" upper_limit="0.4"/>
                    <measurement group_id="O2" value="0.40" lower_limit="0.30" upper_limit="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adherence: Median Scores of Self-reported Adherence to Randomised Study Medications</title>
        <description>AIDS Clinical Trials Group (ACTG) 7-day adherence questionnaire scores. Maximum value is all pills taken every day; minimum value is no pills taken per day. Higher scores indicate a better outcome.</description>
        <time_frame>2 years</time_frame>
        <population>Number of participants attending week 96 visit</population>
        <group_list>
          <group group_id="O1">
            <title>600mg Efavirenz</title>
            <description>Efavirenz 600mg: 3 x EFV 200 mg tablets once daily plus tenofovir/emtricitabine 300 mg/200 mg</description>
          </group>
          <group group_id="O2">
            <title>400mg Efavirenz</title>
            <description>Efavirenz 400 MG: 2 x EFV 200mg tablets plus 1x matched EFV placebo tablet once daily plus tenofovir/emtricitabine 300 mg/200 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Adherence: Median Scores of Self-reported Adherence to Randomised Study Medications</title>
          <description>AIDS Clinical Trials Group (ACTG) 7-day adherence questionnaire scores. Maximum value is all pills taken every day; minimum value is no pills taken per day. Higher scores indicate a better outcome.</description>
          <population>Number of participants attending week 96 visit</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="292"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>All pills taken</title>
                  <measurement_list>
                    <measurement group_id="O1" value="256"/>
                    <measurement group_id="O2" value="271"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Most pills taken</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>About half pills taken</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No pills taken</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasted Insulin Levels</title>
        <description>Change from baseline to week 96 in fasted insulin levels</description>
        <time_frame>Baseline and 2 years</time_frame>
        <population>Available data analysis</population>
        <group_list>
          <group group_id="O1">
            <title>600mg Efavirenz</title>
            <description>Efavirenz 600mg: 3 x EFV 200mg once daily plus tenofovir/emtricitabine 300 mg/200 mg tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>400mg Efavirenz</title>
            <description>Efavirenz 400 MG: 2 x EFV 200mg tablets plus 1x matched EFV placebo tablet once daily plus tenofovir/emtricitabine 300 mg/200 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasted Insulin Levels</title>
          <description>Change from baseline to week 96 in fasted insulin levels</description>
          <population>Available data analysis</population>
          <units>mU per litre</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="321"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" lower_limit="-0.23" upper_limit="1.02"/>
                    <measurement group_id="O2" value="0.3" lower_limit="-1.81" upper_limit="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Selected Serum Biochemical Parameters</title>
        <description>Change from baseline to week 96 in alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase levels between randomised treatment arms</description>
        <time_frame>Baseline and 2 years</time_frame>
        <population>Available data analysis</population>
        <group_list>
          <group group_id="O1">
            <title>600 mg Efavirenz</title>
            <description>EFV 600 mg plus tenofovir 300 mg and emtricitabine 200 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Efavirenz 400 mg</title>
            <description>EFV 400 mg plus tenofovir 300 mg and emtricitabine 200 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Selected Serum Biochemical Parameters</title>
          <description>Change from baseline to week 96 in alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase levels between randomised treatment arms</description>
          <population>Available data analysis</population>
          <units>Units per Litre</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="321"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alanine aminotransferase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="285"/>
                    <count group_id="O2" value="298"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.53" lower_limit="1.04" upper_limit="12.02"/>
                    <measurement group_id="O2" value="0.64" lower_limit="-3.52" upper_limit="4.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate aminotransferase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="283"/>
                    <count group_id="O2" value="297"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" lower_limit="-1.69" upper_limit="5.10"/>
                    <measurement group_id="O2" value="-1.23" lower_limit="-3.67" upper_limit="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline phosphatase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="284"/>
                    <count group_id="O2" value="299"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.75" lower_limit="22.9" upper_limit="30.61"/>
                    <measurement group_id="O2" value="21.23" lower_limit="17.4" upper_limit="25.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Estimate Creatinine Clearance</title>
        <description>Change from baseline to week 96 in estimate creatinine clearance between randomised treatment arms</description>
        <time_frame>Baseline and 2 years</time_frame>
        <population>Available data analysis</population>
        <group_list>
          <group group_id="O1">
            <title>600mg Efavirenz</title>
            <description>Efavirenz: 3 x EFV 200mg tablets once daily plus tenofovir/emtricitabine 300 mg/200 mg</description>
          </group>
          <group group_id="O2">
            <title>400mg Efavirenz</title>
            <description>Efavirenz: 2 x EFV 200mg tablets plus 1x matched EFV placebo tablet once daily plus tenofovir/emtricitabine 300 mg/200 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Estimate Creatinine Clearance</title>
          <description>Change from baseline to week 96 in estimate creatinine clearance between randomised treatment arms</description>
          <population>Available data analysis</population>
          <units>millilitres per minute</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="321"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" lower_limit="-2.45" upper_limit="2.10"/>
                    <measurement group_id="O2" value="1.59" lower_limit="-1.05" upper_limit="4.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Steady-state Efavirenz Concentrations</title>
        <description>Steady-state efavirenz mid-dosing interval plasma concentrations</description>
        <time_frame>Week 4</time_frame>
        <population>Available data analysis</population>
        <group_list>
          <group group_id="O1">
            <title>600mg Efavirenz</title>
            <description>Efavirenz: 3 x EFV 200mg tablets once daily plus tenofovir/emtricitabine 300 mg/200 mg</description>
          </group>
          <group group_id="O2">
            <title>400mg Efavirenz</title>
            <description>Efavirenz: 2 x EFV 200mg tablets plus 1x matched EFV placebo tablet once daily plus tenofovir/emtricitabine 300 mg/200 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Steady-state Efavirenz Concentrations</title>
          <description>Steady-state efavirenz mid-dosing interval plasma concentrations</description>
          <population>Available data analysis</population>
          <units>milligram per Litre</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="311"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.85" lower_limit="2.70" upper_limit="3.0"/>
                    <measurement group_id="O2" value="2.10" lower_limit="2.01" upper_limit="2.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>96 weeks. Analyses were modified intention-to-treat which included all randomised participants who received at least one dose of study drug and had at least one follow-up visit. Number of participants in the modified ITT analysis at week 96 are: 321 for EFV 400mg and 309 for EFV 600mg</time_frame>
      <desc>Adverse event analysis included all randomised participants who received at least one dose of study drug and had at least one follow-up visit. Number of participants in this modified ITT analysis at week 96 are: 321 for EFV 400mg and 309 for EFV 600mg</desc>
      <group_list>
        <group group_id="E1">
          <title>600mg Efavirenz</title>
          <description>Eligible patients will be centrally randomised to receive tenofovir (TDF) (300mg qd)/emtricitabine (FTC) (200mg qd) + EFV (600mg qd; 3 x 200mg qd)
Efavirenz: 3 x EFV 200mg tablets once daily</description>
        </group>
        <group group_id="E2">
          <title>400mg Efavirenz</title>
          <description>Eligible patients will be centrally randomised to receive TDF (300mg qd)/FTC (200mg qd) + EFV (400mg qd; 2 x 200mg + 1 x 200mg placebo qd).
Efavirenz: 2 x EFV 200mg tablets plus 1x matched EFV placebo tablet once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="309"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="309"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>lymphadenopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>visual disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>anal fissure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>hepatitis C</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>lip oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Stevens-Johnson syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>bacterial pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>bacterial diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>gastroenteritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="309"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>urosepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>dengue fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>perianal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>cerebral toxoplasmosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>disseminated tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>skin laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>abortion spontaneous incomplete</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>nephrotic syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>testicular seminoma stage II</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>priapism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>testicular injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash macro-papular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>breast lump removal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>subdural haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="273" subjects_at_risk="309"/>
                <counts group_id="E2" subjects_affected="286" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhoea</sub_title>
                <counts group_id="E1" events="40" subjects_affected="36" subjects_at_risk="309"/>
                <counts group_id="E2" events="38" subjects_affected="33" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="24" subjects_affected="22" subjects_at_risk="309"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="41" subjects_affected="36" subjects_at_risk="309"/>
                <counts group_id="E2" events="68" subjects_affected="57" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <counts group_id="E1" events="26" subjects_affected="18" subjects_at_risk="309"/>
                <counts group_id="E2" events="30" subjects_affected="26" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>influenza</sub_title>
                <counts group_id="E1" events="22" subjects_affected="17" subjects_at_risk="309"/>
                <counts group_id="E2" events="23" subjects_affected="18" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>gastroenteritis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="309"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="40" subjects_affected="34" subjects_at_risk="309"/>
                <counts group_id="E2" events="44" subjects_affected="35" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>abnormal dreams</sub_title>
                <counts group_id="E1" events="35" subjects_affected="35" subjects_at_risk="309"/>
                <counts group_id="E2" events="29" subjects_affected="28" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="309"/>
                <counts group_id="E2" events="21" subjects_affected="20" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="309"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="44" subjects_affected="41" subjects_at_risk="309"/>
                <counts group_id="E2" events="65" subjects_affected="57" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="121" subjects_affected="107" subjects_at_risk="309"/>
                <counts group_id="E2" events="96" subjects_affected="85" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sean Emery</name_or_title>
      <organization>University of New South Wales</organization>
      <phone>02 9385 0900</phone>
      <email>semery@kirby.unsw.edu.au</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

